Research ArticleArticle
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
Ruben Queiro, Juan D. Cañete, Carlos Montilla, Miguel Angel Abad, María Montoro, Susana Gómez and Ana Cábez for the MAAPS Study Group
The Journal of Rheumatology February 2019, jrheum.180460; DOI: https://doi.org/10.3899/jrheum.180460
Ruben Queiro
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
Juan D. Cañete
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
Carlos Montilla
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
Miguel Angel Abad
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
María Montoro
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
Susana Gómez
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
Ana Cábez
From the Department of Rheumatology, Hospital Universitario Central de Asturias, Oviedo; Department of Rheumatology, Hospital Universitario Clinic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca; Department of Rheumatology, Hospital Virgen del Puerto, Plasencia; Medical Department, Pfizer, Madrid, Spain. This study was funded by Pfizer SLU. R. Queiro, MD, PhD, Department of Rheumatology, Hospital Universitario Central de Asturias; J.D. Cañete, MD, PhD, Department of Rheumatology, Hospital Universitario Clinic de Barcelona and IDIBAPS; C. Montilla, MD, Department of Rheumatology, Hospital Universitario de Salamanca; M.A. Abad, MD, Department of Rheumatology, Hospital Virgen del Puerto; M. Montoro, MD, Medical Department, Pfizer; S. Gómez, MD, Medical Department, Pfizer; A. Cábez, MD, Medical Department, Pfizer. Address correspondence to Dr. R. Queiro, Av. Roma, s/n, 33011 Oviedo, Asturias, Spain. E-mail: rubenque7@yahoo.es. Accepted for publication October 16, 2018.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
Ruben Queiro, Juan D. Cañete, Carlos Montilla, Miguel Angel Abad, María Montoro, Susana Gómez, Ana Cábez
The Journal of Rheumatology Feb 2019, jrheum.180460; DOI: 10.3899/jrheum.180460